For how we live.
In PANKU-Lung01, 432 people with EGFR-mutated NSCLC that progressed on a third-generation EGFR tablet got izalontamab brengitecan or chemotherapy. Median progression-free survival was 11.1 versus 5.7 months.
In HERON-Lung01, 498 people in China with EGFR-mutated NSCLC that had progressed after a targeted drug were randomised to ruzaltatug rezetecan or chemotherapy. Median progression-free survival was 8.3 versus 5.4 months.
In a phase 3 trial, 314 people with EGFR-mutated, MET-amplified NSCLC progressing after a targeted drug were randomised to dalmelitinib plus aumolertinib or chemotherapy. Median PFS was 6.2 versus 4.4 months.
Creatinine is muscle waste your kidneys clear; eGFR is an estimate of filtering capacity built from it. A single reading is a snapshot, not a diagnosis — and the equations have limits worth knowing.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.